Impact Biosystems develops adaptive hardware and software services that provide personalized active recovery by tracking users' muscle profiles and responding in real time. Its system is based on proven methods used for professional athletes and on MIT research. The device employs a proprietary electromagnetic actuator for greater accuracy, precision, and real-time monitoring, distinguishing it from crank-piston mechanisms. The company emphasizes active recovery benefits such as increased blood flow, toxin elimination, reduced soreness, and maintained muscle flexibility. The founding team includes Ian Hunter (Chief Inventor), Sonny Vu (Executive Chairman), Bridget Hunter-Jones (CEO), and Craig Cheney (CTO), with deep consumer-product and MIT expertise. Headquartered in Boston and founded in 2019, Impact recently closed $4.5M in new funding to help bring its technology to market.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2021